Weekly Investment Analysts’ Ratings Updates for 10x Genomics (TXG)

Several analysts have recently updated their ratings and price targets for 10x Genomics (NASDAQ: TXG):

• 7/17/2026 – 10x Genomics had its price target raised by Leerink Partners from $23.00 to $40.00. They now have a “market perform” rating on the stock.
• 7/15/2026 – 10x Genomics had its “hold” rating reaffirmed by TD Cowen.
• 7/14/2026 – 10x Genomics had its price target raised by Canaccord Genuity Group Inc. from $32.00 to $50.00. They now have a “buy” rating on the stock.
• 7/9/2026 – 10x Genomics had its price target raised by Morgan Stanley from $22.00 to $37.00. They now have an “equal weight” rating on the stock.
• 7/8/2026 – 10x Genomics had its price target raised by Citigroup Inc. from $24.00 to $45.00. They now have a “neutral” rating on the stock.
• 7/1/2026 – 10x Genomics had its price target raised by Piper Sandler from $20.00 to $42.00. They now have a “neutral” rating on the stock.
• 6/24/2026 – 10x Genomics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/24/2026 – 10x Genomics had its price target raised by Barclays PLC from $30.00 to $40.00. They now have an “overweight” rating on the stock.

Insiders Place Their Bets

In other news, CFO Adam Taich sold 15,098 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $24.44, for a total value of $368,995.12. Following the transaction, the chief financial officer directly owned 379,898 shares of the company’s stock, valued at $9,284,707.12. The trade was a 3.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Benjamin J. Hindson sold 11,595 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $24.44, for a total value of $283,381.80. Following the transaction, the insider owned 502,000 shares in the company, valued at $12,268,880. The trade was a 2.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 91,309 shares of company stock valued at $2,581,357 over the last 90 days. 8.84% of the stock is owned by company insiders.

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.